Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study-MedSci.cn

Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study

Hyman, D; Hendifar, A; Chung, HC; Maio, M; Leary, A; Spanggaard, I; Rhee, J; Marton, M; Chen, MH; Krishnan, S; Shapira, R

CANCER RESEARCH, 2019; 79 (13):